C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show a rise in quarterly revenue when it reports results on February 26 (estimated) for the period ending December 31 2024
The Watertown Massachusetts-based company is expected to report a 57.2% increase in revenue to $5.125 million from $3.26 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for C4 Therapeutics Inc is for a loss of 48 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for C4 Therapeutics Inc is $13.00, above its last closing price of $3.01.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.36 | -0.38 | -0.35 | Beat | 7.9 |
Jun. 30 2024 | -0.37 | -0.37 | -0.26 | Beat | 30 |
Mar. 31 2024 | -0.36 | -0.35 | -0.41 | Missed | -16.7 |
Dec. 31 2023 | -0.64 | -0.68 | -0.70 | Missed | -2.6 |
Sep. 30 2023 | -0.67 | -0.66 | -0.52 | Beat | 21.2 |
Jun. 30 2023 | -0.69 | -0.69 | -0.73 | Missed | -6.1 |
Mar. 31 2023 | -0.73 | -0.75 | -0.71 | Beat | 4.8 |
Dec. 31 2022 | -0.73 | -0.74 | -0.77 | Missed | -3.5 |
This summary was machine generated February 24 at 13:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。